Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
You may also be interested in...
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?
2021 was a busy year in the medtech investment space. How will 2022 compare?